EDUCATION > Educational Programs > E-Learning > Videos/Webcasts > 2012 Annual Meeting Webcasts > Advanced Prostate Cancer > Module 3: Management of Castration Resistant Prostate Cancer

Module 3: Management of Castration Resistant Prostate Cancer

Activity Description

This activity will introduce participants to the challenges and gratification of being involved in the medical treatment of patients with castration resistant prostate cancer (CRPC). A practical approach to using chemotherapy and bisphosphonates as well as managing their side effects will be discussed. Some promising agents in clinical trials will be reviewed.

Learning Objectives

After participating in this activity, participants should be able to:

  • cite presently available options for managing bone related issues in CRPC
  • describe available and future systemic (both intra-venous and oral) options for managing CRPC
  • review through clinical cases practical aspects in the management of CRPC

Faculty/Authors

Paul R. Sieber, MD, Course Director
Urological Associates of Lancaster
Lancaster, PA
Disclosures: Wilex: Scientific Study or Trial ; Spectrum: Scientific Study or Trial ; Nymox: Scientific Study or Trial ; Sanofi Synthelabo: Scientific Study or Trial ; GTX: Health Publishing,Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; POM Wonderful: Scientific Study or Trial ; Bavarian Nordic: Scientific Study or Trial ; Medivation/Astellas: Scientific Study or Trial ; ENDO: Scientific Study or Trial ; Ferring: Meeting Participant or Lecturer,Scientific Study or Trial ; Amgen: Health Publishing,Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; watson: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; Auxillium: Consultant or Advisor,Scientific Study or Trial ; Millenium: Scientific Study or Trial ; ActiveBiotech: Scientific Study or Trial

Fred Saad, MD, FRCS, Course Director
Professor and Chief of Urology
University of Montreal Hospital Center
Montreal, QC
Discosures: Novartis: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; Amgen: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; Sanofi Aventis: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; Astellas: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; Millenium: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; BMS: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial

Joel B. Nelson, MD
Department Head, Urology
University of Pittsburgh Medical Center
Pittsburgh, PA
Disclosures: Amgen: Consultant or Advisor ; Astra Zeneca: Scientific Study or Trial ; Bayer HealthCare Pharmaceuticals: Consultant or Advisor ; Atellas/Medivation: Consultant or Advisor ; Millenium/Takeda: Consultant or Advisor,Scientific Study or Trial

Acknowledgement for Support

Support provided by educational grants from the following companies:

AMGEN Astellas Janseen
Medivation Millennium


Agus DB, et al. ASCO 2011, Chicago, IL, USA (Abstract 4531).

April 2010. Kantoff PW et al. NEJM 2010;363:411-422.

Attard, J Clin Oncol, 26:4563, 2008

Berthold et al, J Clin Oncol; 2008

Boyle WJ, et al. Nature. 2003;423:337-342.

Brown J et al. J Natl Cancer Inst. 2005;97:59.

Chambers CA, et al. Annu Rev Immunol. 2001;19:565-594.

Chi KN et al, J Clin Oncol, 28: 4247, 2010

Chi, J Clin Oncol 30, 2012 (suppl 5; abstr 15)

Clinical Trials, http://www.clinicaltrials.gov/ct2/show/NCT00744497

Clinical Trials, www.clinicaltrials.gov: NCT0069975
Clinical Trials, www.clinicaltrials.gov; accessed June 2011

De Bono et al. Lancet. 2010;376:1147-1154

Dreicer R, et al. ASCO-GU 2010, San Francisco, CA, USA (Abstract 103).

Fizazi K et al. Lancet. 2011;377(9768):813-822.

Fizazi K, et al. J Clin Oncol. 2009 Feb 23. [Epub ahead of print].

Fizzazi et al. Lancet 2011

Health Canada 2005. www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2005/zometa_aclasta_hpc-cps-eng.php

http://www.sheffield.ac.uk/FRAX/.

Hussain M, et al. Presented at: Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2011; Chicago, IL.

Kaku T, et al. ACS 2010, Boston, MA, USA (Abstract 96).
Yamaoka M, et al. AACR Annual Meeting 2010, Washington DC, USA (Abstract DD01-03).

Kantoff P W et al. JCO 2010;28:1099-1105

Logothetis, ASCO, 2011

Parker C, et al. Presented at EMCC 2011. Stockholm, Sweden. September 24, 2011.

Saad et al. Urologic Oncology Dec 2010

Saad F, et al. Cancer. 2007;110(8):1860-1867

Saad F, et al. J Natl Cancer Inst. 2004;96:879-882

Saad F, et al. UROLOGY 76: 1175–1181, 2010.

Saylor PJ, et al. J Urol. 2010;183:2200-2205.

Shahinian VB, et al. N Engl J Med. 2005;352:154-164.

Shirina N, et al. Presented at ASCO 2006. Poster 8529.

Smith MR, et al. J Clin Oncol. 2005;23(13):2918-2925.

Smith, MR et al. Lancet. 2011

Smith, Saad et al. Lancet 2012

Tannock I. J Clin Oncol 1996;14:1756

Tannock IF, et al. N Engl J Med 2004;351:1502-1512.

ADVERTISEMENT

ADVERTISEMENT
Donate
Contact
Press/Media
Sections
Term of Use
Site Map


ADVERTISEMENT